Thyroid function outcomes after pegylated interferon-α and ribavirin therapy for chronic hepatitis C

Endocrine Practice

Volumn 16, Issue 6, 2010, Pages 934-939

  Tran, Huy A ^a   Reeves, Glenn E M ^a   Ianna, Elizabeth A ^b   Leembruggen, Nadine ^b  

^a JOHN HUNTER HOSPITAL   (Australia)

^b JOHN HUNTER HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ANTIBODY; BILIRUBIN; GAMMA GLUTAMYLTRANSFERASE; HEMOGLOBIN; HUMAN THYROID RECEPTOR ANTIBODY; LIOTHYRONINE; PEGINTERFERON ALPHA; PROPRANOLOL; RIBAVIRIN; THYROGLOBULIN ANTIBODY; THYROID STIMULATING IMMUNOGLOBULIN; THYROPEROXIDASE ANTIBODY; THYROTROPIN; THYROXINE; UNCLASSIFIED DRUG;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ANTIBODY DETECTION; ANTIVIRAL THERAPY; ARTICLE; BILIRUBIN BLOOD LEVEL; CLINICAL EVALUATION; DRUG WITHDRAWAL; DYSPNEA; ECHOGRAPHY; FEMALE; FREE LIOTHYRONINE INDEX; FREE THYROXINE INDEX; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GENOTYPE; HEART PALPITATION; HEAT INTOLERANCE; HEMOGLOBIN BLOOD LEVEL; HEPATITIS C; HUMAN; HYPOTHYROIDISM; LEUKOCYTE COUNT; LIVER FUNCTION TEST; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PROSPECTIVE STUDY; PROTHROMBIN TIME; THROMBOCYTE COUNT; THYROID FUNCTION; THYROID FUNCTION TEST; THYROIDITIS; THYROTOXICOSIS; THYROTROPIN BLOOD LEVEL; TREATMENT DURATION; TREATMENT FAILURE; VIRUS LOAD;

ADULT; ANTIVIRAL AGENTS; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RIBAVIRIN; THYROID FUNCTION TESTS; THYROID GLAND; THYROTROPIN; THYROXINE; TRIIODOTHYRONINE;

EID: 79952396188     PISSN: 1530891X     EISSN: None     Source Type: Journal    
DOI: 10.4158/EP10036.OR     Document Type: Article

References (20)

1. World Health Organization. Hepatitis C. Factsheet No. 164, revised October 2000. https://apps.who.int/inf-fs/en/fact164.html. Accessed for verification August 15, 2010.
2. Yohannes K, Roche P, Blumer C, et al. Australia's notifiable diseases status, 2002: annual report of the National Notifiable Diseases Surveillance System. Commun Dis Intell. 2004;28:6-68.
3. Armstrong GL, Wasley N, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med. 2006;144:705-714.
4. Dienstag JL. Hepatitis C: a bitter harvest. Ann Intern Med. 2006;144:770-771.
5. Patel K, Muir AJ, McHutchison JG. Diagnosis and treatment of chronic hepatitis C infection. BMJ. 2006;332:1013-1017. (Pubitemid 44365522)
6. Moreno-Otero R. Therapeutic modalities in hepatitis C: challenges and development. J Viral Hepat. 2005;12:10-19. (Pubitemid 40188769)
7. Carella C, Mazziotti G, Amato G, Braverman LE, Roti E. Clinical review 169: interferon-alpha-related thyroid disease; pathophysiological, epidemiological, and clinical aspects. J Clin Endocrinol Metab. 2004;89:3656-3661.
8. Tran HA. Hepatitis C infection, treatment regimens, and thyroid function abnormalities. Endocrinologist. 2007;17:231-235. (Pubitemid 47220779)
9. Prummel MF, Laurberg P. Interferon-alpha and autoimmune thyroid disease. Thyroid. 2003;13:547-551.
10. François C, Castelain S, Duverlie G, Capron D, Nguyen-Khac E. Optimizing the treatment of chronic viral hepatitis C. Expert Rev Gastroenterol Hepatol. 2009;3:607-613.
11. Tran HA, Jones TL, Batey RG. The spectrum of thyroid dysfunction in an Australian hepatitis C population treated with combination interferon-alpha2beta and ribavirin. BMC Endocr Disord. 2005;5:8.
12. Carella C, Mazziotti G, Morisco F, et al. Long-term outcome of interferon-alpha-induced thyroid autoimmunity and prognostic influence of thyroid autoantibody pattern at the end of treatment. J Clin Endocrinol Metab. 2001;86:1925-1929. (Pubitemid 32472899)
13. Doi F, Kakizaki S, Takagi H, et al. Long-term outcome of interferon-alpha-induced autoimmune thyroid disorders in chronic hepatitis C. Liver Int. 2005;25:242-246.
14. Morisco F, Mazziotti G, Rotondi M, et al. Interferon-related thyroid autoimmunity and long-term clinical outcome of chronic hepatitis C. Dig Liver Dis. 2001;33:247-253. (Pubitemid 32452058)
15. Tong MJ, Reddy KR, Lee WM, et al (Consensus Interferon Study Group). Treatment of chronic hepatitis C with consensus interferon: a multicenter, randomized, controlled trial. Hepatology. 1997;26:747-754. (Pubitemid 27392369)
16. Vezali E, Elefsiniotis I, Mihas C, Konstantinou E, Saroglou G. Thyroid dysfunction in patients with chronic hepatitis C: virus- or therapy-related? J Gastroenterol Hepatol. 2009;24:1024-1029.
17. Fabbri C, Jaboli MF, Giovanelli S, et al. Gastric autoimmune disorders in patients with chronic hepatitis C before, during and after interferon-alpha therapy. World J Gastroenterol. 2003;9:1487-1490. (Pubitemid 36992338)
18. Betterle C, Fabris P, Zanchetta R, et al. Autoimmunity against pancreatic islets and other tissues before and after interferon-alpha therapy in patients with hepatitis C virus chronic infection. Diabetes Care. 2000;23:1177-1181. (Pubitemid 30616809)
19. Minelli R, Braverman LE, Valli MA, et al. Recombinant interferon alpha (rIFN-alpha) does not potentiate the effect of iodine excess on the development of thyroid abnormalities in patients with HCV chronic active hepatitis. Clin Endocrinol (Oxf). 1999;50:95-100. (Pubitemid 29079373)
20. Wong VW, Cheng AY, Chan HL. Interferon-induced thyroid dysfunction - not always transient. J Gastroenterol Hepatol. 2009;24:938-940.